公开(公告)号：US11912752B2

公开(公告)日：2024-02-27

申请号：US17243589

申请日：2021-04-29

申请人： Dehong Yang

发明人： Dehong Yang

IPC分类号： C07K14/635 ,  A61P19/10 ,  A61K38/00

CPC分类号： C07K14/635 ,  A61P19/10 ,  A61K38/00

摘要： A novel PTH(1-34) mimetic peptide based on protein domain reconstruction. The mimetic peptide contains peptide fragment repeats at 29th-34th positions. The amino acid at the 34th position and the last amino acid of the peptide fragment repeats at the 29th-34th positions are changed from phenylalanine (Phe, F) into tyrosine (Tyr, Y), so that MY-3 peptide is formed. Preclinical experiments show that the MY-3 mimetic peptide promotes osteoblast differentiation and has a very good effect in treating osteoporosis and promoting bone growth. The anti-osteoporosis effect of the MY-3 mimetic peptide is better than that of the PTH (1-34) (The product name on the market is Forsteo or Parathyroid), so that the MY-3 mimetic peptide has a significant clinical application prospect.

公开(公告)号：US20240209057A1

公开(公告)日：2024-06-27

申请号：US18412585

申请日：2024-01-14

申请人： Dehong YANG

发明人： Dehong YANG

IPC分类号： C07K14/635 ,  A61K38/00 ,  A61P19/10

CPC分类号： C07K14/635 ,  A61P19/10 ,  A61K38/00

摘要： A PTH(1-34) mimetic peptide and a pharmaceutical composition for preventing or treating osteoporosis or promoting bone growth are provided. The mimetic peptide contains peptide fragment repeats at 29th-34th positions. Structure of the mimetic peptide is PTH(1-F34Y)(29-F34Y), and the amino acid sequence of the mimetic peptide is SEQ ID NO: 3. The pharmaceutical composition includes an active ingredient and a pharmaceutically acceptable carrier. The active ingredient of the pharmaceutical composition contains the PTH mimetic peptide.

公开(公告)号：US20210253663A1

公开(公告)日：2021-08-19

申请号：US17243589

申请日：2021-04-29

申请人： Dehong YANG

发明人： Dehong YANG

IPC分类号： C07K14/635 ,  A61P19/10

摘要： A novel PTH(1-34) mimetic peptide based on protein domain reconstruction. The mimetic peptide contains peptide fragment repeats at 29th-34th positions. The amino acid at the 34th position and the last amino acid of the peptide fragment repeats at the 29th-34th positions are changed from phenylalanine (Phe, F) into tyrosine (Tyr, Y), so that MY-3 peptide is formed. Preclinical experiments show that the MY-3 mimetic peptide promotes osteoblast differentiation and has a very good effect in treating osteoporosis and promoting bone growth. The anti-osteoporosis effect of the MY-3 mimetic peptide is better than that of the PTH (1-34) (The product name on the market is Forsteo or Parathyroid), so that the MY-3 mimetic peptide has a significant clinical application prospect.